Faeth Therapeutics Q2 2026: $16M Net Loss, $186M Cash, and PIKTOR Data Expected by Year-End
FTH has more than doubled off its 52-week low of $7.1 on elevated volume (2.1× avg).
Summary
Faeth Therapeutics reported a $16M net loss for Q2 2026, ending the quarter with $186.4M in cash. Topline Phase 2 PIKTOR data in endometrial cancer is expected by year-end, and dosing has begun in a breast cancer trial.
Key Events · Earnings and Guidance · FTH
-
Q2 2026 Financial Results
Operating expenses climbed to $18.4 million from $5.2 million in Q2 2025, driven by the post-merger ramp in R&D and G&A, resulting in a net loss of $16.0 million, or $2.84 per share.
-
Strong Cash Position
Cash, equivalents, and marketable securities stood at $186.4 million as of June 30, 2026, a sharp increase from $21.2 million at year-end 2025, following the $200 million PIPE financing.
-
PIKTOR Phase 2 Data on Track
A key near-term catalyst, topline results from the Phase 2 PIK-201 trial in endometrial cancer, are expected by year-end 2026.
-
Breast Cancer Trial Initiated
In April 2026, the first patient was dosed in the Phase 1b/2 PIK-101 trial of PIKTOR in HR+/HER2- advanced breast cancer; initial safety and efficacy data are anticipated in 2027.
Analysis · FTH · Life Sciences
A $16.0 million net loss in Q2 2026 reflects the expected ramp in R&D and G&A spending following Faeth Therapeutics' combination with Sensei Biotherapeutics. With $186.4 million in cash, the company has ample runway to advance its lead oncology program, PIKTOR. Topline Phase 2 data in endometrial cancer remains on track for year-end 2026, and the first patient has been dosed in a Phase 1b/2 breast cancer trial. These results mark the new entity's first full quarter after the merger and $200 million PIPE financing, with spending increasing as planned. For a clinical-stage biotech, the cash position and upcoming catalyst make this a notable update.
At the time of this filing, FTH was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $704.8M. The 52-week trading range was $7.10 to $37.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.